LEXX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 geg. 2024 @ 23:00):

Stats
Šios dienos apimtis	343 955
Vidutinė apimtis	478 383
Rinkos kapitalizacija	37.63M
EPS	$0 ( 2024-04-12 )
Kita pelno data	( $-0.130 ) 2024-07-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.36
ATR14	$0.0280 (0.96%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-14	Carle Vanessa	Sell	2 500	Stock Options
2024-05-14	Carle Vanessa	Buy	2 500	common shares
2024-04-26	Carle Vanessa	Buy	10 000	Stock Options
2024-04-26	Turkel Catherine C.	Buy	5 000	Stock Options
2024-04-26	Baxter Nicholas W	Buy	5 000	Stock Options

INSIDER POWER
10.87
Last 99 transactions
Buy: 3 496 310 \| Sell: 1 994 235

Tūris Koreliacija

Ilgas: -0.01 (neutral)

Trumpas: 0.27 (neutral)

Signal:(48.242) Neutral

Lexaria Bioscience Corp. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
AIHS	0.867
PASG	0.86
POWL	0.856
SLN	0.856
VTYX	0.856
CLBT	0.851
MRUS	0.85
KYMR	0.85
PEPG	0.847
QRTEP	0.845

10 Labiausiai neigiamai susiję koreliacijos
MDRX	-0.823
DPRO	-0.816

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Lexaria Bioscience Corp. Koreliacija - Valiuta/Žaliavos

0.39
( neutral )

0.13
( neutral )

0.00
( neutral )

0.51
( weak )

0.29
( neutral )

-0.75
( moderate negative )

Lexaria Bioscience Corp. Finansinės ataskaitos

Annual	2023
Pajamos:	$226 208
Bruto pelnas:	$194 708 (86.07 %)
EPS:	$-1.010

FY	2023
Pajamos:	$226 208
Bruto pelnas:	$194 708 (86.07 %)
EPS:	$-1.010

FY	2022
Pajamos:	$255 397
Bruto pelnas:	$183 556 (71.87 %)
EPS:	$-1.240

FY	2021
Pajamos:	$722 738
Bruto pelnas:	$547 392 (75.74 %)
EPS:	$-0.950

Financial Reports:

No articles found.

Lexaria Bioscience Corp. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Lexaria Bioscience Corp.

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.